Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026

One-on-one and group investor meetings at Morgan Stanley’s 24 th Annual Healthcare Conference on Monday, September 14, 2026

A fireside chat at the H.C. Wainwright 28 th Annual Global Investment Conference at 1:30 p.m. ET on Tuesday, September 15, 2026

Live webcasts of the fireside chats are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com , where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X , formerly known as Twitter.

Investor Contact

Megan LeDuc Associate Director, Investor Relations [email protected]

Media Contact

David Rosen Argot Partners [email protected]